8 results on '"Eleveld, Douglas J."'
Search Results
2. Mechanism-based pharmacodynamic model for propofol haemodynamic effects in healthy volunteers☆.
- Author
-
Su, Hong, Eleveld, Douglas J., Struys, Michel M.R.F., and Colin, Pieter J.
- Subjects
- *
HEMODYNAMICS , *PROPOFOL , *HEART beat , *HUMAN research subjects , *GENERAL anesthesia , *INTRAVENOUS anesthetics - Abstract
Background: The adverse haemodynamic effects of the intravenous anaesthetic propofol are well known, yet few empirical models have explored the dose-response relationship. Evidence suggests that hypotension during general anaesthesia is associated with postoperative mortality. We developed a mechanism-based model that quantitatively characterises the magnitude of propofol-induced haemodynamic effects during general anaesthesia.Methods: Mean arterial pressure (MAP), heart rate (HR) and pulse pressure (PP) measurements were available from 36 healthy volunteers who received propofol in a step-up and step-down fashion by target-controlled infusion using the Schnider pharmacokinetic model. A mechanistic pharmacodynamic model was explored based on the Snelder model. To benchmark the performance of this model, we developed empirical models for MAP, HR, and PP.Results: The mechanistic model consisted of three turnover equations representing total peripheral resistance (TPR), stroke volume (SV), and HR. Propofol-induced changes were implemented by Emax models on the zero-order production rates of the turnover equations for TPR and SV. The estimated 50% effective concentrations for propofol-induced changes in TPR and SV were 2.96 and 0.34 μg ml-1, respectively. The goodness-of-fit for the mechanism-based model was indistinguishable from the empirical models. Simulations showed that predictions from the mechanism-based model were similar to previously published MAP and HR observations.Conclusions: We developed a mechanism-based pharmacodynamic model for propofol-induced changes in MAP, TPR, SV, and HR as a potential approach for predicting haemodynamic alterations.Clinical Trial Registration: NCT02043938. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
3. Resisting neural inertia: an exercise in floccinaucinihilipilification?
- Author
-
Eleveld, Douglas J., Colin, Pieter J., Absalom, Anthony R., and Struys, Michel M.R.F.
- Subjects
- *
PHARMACOLOGY , *PHARMACODYNAMICS , *HYSTERESIS loop - Published
- 2021
- Full Text
- View/download PDF
4. Target-controlled-infusion models for remifentanil dosing consistent with approved recommendations.
- Author
-
Eleveld, Douglas J., Colin, Pieter, Absalom, Anthony R., and Struys, Michel M.R.F.
- Subjects
- *
LABELS , *OLDER people , *DRUG dosage , *PHARMACOKINETICS , *DRUG administration , *BIOLOGICAL models , *RESEARCH , *INTRAVENOUS therapy , *RESEARCH methodology , *EVALUATION research , *MEDICAL cooperation , *COMPARATIVE studies - Abstract
Background: Target-controlled infusion (TCI) systems use pharmacokinetic (PK) models to predict the drug infusion rates necessary to achieve a desired target plasma or effect-site concentration. As new PK models are developed and implemented in TCI systems, there can be uncertainty as to which target concentrations are appropriate. Existing dose recommendations can serve as a point of reference to identify target concentrations suitable for clinical applications.Methods: Simulations of remifentanil TCI were performed using three PK models (Minto, Eleveld, and Kim). We sought to identify models and target concentrations for remifentanil administration in children, adult, older people, and severely obese individuals, consistent with the remifentanil product label. In a typical adult this is an induction dose of 0.5-1 μg kg-1 and starting maintenance infusion rate of 0.25 μg kg-1 min-1.Results: For the Minto, Eleveld, and Kim remifentanil models, a plasma target concentration of ∼ 4 ng ml-1 achieves drug administration consistent with product label recommended initial doses for all groups with minor exceptions. With effect-site targeting in older individuals, a target concentration of ∼2 ng ml-1 is required for induction and ∼4 ng ml-1 for starting maintenance to achieve drug dosages close to product label recommendations.Conclusions: We identified remifentanil TCI target concentrations that resulted in drug administration similar to product label dosing recommendations. This approach did not necessarily identify target concentrations that achieve desired clinical effect, only those that are consistent with the product label recommended doses. We estimate that plasma target concentrations of 3.1-5.3 ng ml-1 are suitable for initial dosing. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
5. Pharmacodynamic mechanism-based interaction model for the haemodynamic effects of remifentanil and propofol in healthy volunteers.
- Author
-
Su, Hong, Koomen, Jeroen V., Eleveld, Douglas J., Struys, Michel M.R.F., and Colin, Pieter J.
- Subjects
- *
REMIFENTANIL , *PROPOFOL , *HEMODYNAMICS , *VOLUNTEERS , *VOLUNTEER service - Abstract
Propofol and remifentanil are frequently combined for the induction and maintenance of general anaesthesia. Both propofol and remifentanil cause vasodilation and potentially reduce arterial BP. We aimed to develop a mechanism-based model that characterises the haemodynamic interactions between remifentanil and propofol. Data from two clinical trials in healthy volunteers were analysed using remifentanil-alone, propofol-alone, and combination groups. We evaluated remifentanil effects on haemodynamics using a previously developed mechanism-based haemodynamic model of propofol. The interaction between propofol and remifentanil was explored using the principles of the general pharmacodynamic interaction (GPDI) model. Remifentanil alone increased the dissipation rate of total peripheral resistance by 50% at 3.0 ng ml−1. Additionally, the dissipation rates of HR and stroke volume were attenuated by 4.8% and 4.9% per 1 ng ml−1 increase in remifentanil concentration, respectively. The maximal effect of propofol alone in decreasing the production rate of total peripheral resistance was 78%, which decreased to 32% when combined with remifentanil 4 ng ml−1. The effects of remifentanil on HR and stroke volume were attenuated by propofol with maximum decreases of 11.9% and 21.2%, respectively. Goodness-of-fit plots and prediction-corrected visual predictive check plots showed good predictive performance of the models. The structure of the previous mechanism-based haemodynamic model for propofol was able to describe the effects of remifentanil alone on haemodynamic variables. The GPDI model provided a good framework for characterising the pharmacodynamic interaction between remifentanil and propofol on haemodynamic properties. NCT02043938; NCT03143972. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
6. Neuromuscular end-point predictive capability of published rocuronium pharmacokinetic/pharmacodynamic models: An observational trial.
- Author
-
Carvalho, Hugo, Verdonck, Michaël, Eleveld, Douglas J., Ramirez, David, D'Haese, Jan, Flamée, Panagiotis, Geerts, Lieselot, Wylleman, Jasper, Cools, Wilfried, Barbe, Kurt, Struys, Michel M.R.F., and Poelaert, Jan
- Subjects
- *
ROCURONIUM bromide , *PHARMACOKINETICS , *INTRAOPERATIVE monitoring , *ELECTIVE surgery , *CLINICAL prediction rules , *CONFIDENCE intervals - Abstract
Objective neuromuscular monitoring remains the single most reliable method to ensure optimal perioperative neuromuscular management. Nevertheless, the prediction of clinical neuromuscular endpoints by means of Pharmacokinetic (PK) and Pharmacodynamic (PD) modelling has the potential to complement monitoring and improve perioperative neuromuscular management.s The present study aims to assess the performance of published Rocuronium PK/PD models in predicting intraoperative Train-of-four (TOF) ratios when benchmarked against electromyographic TOF measurements. Observational trial. Tertiary Belgian hospital, from August 2020 up to September 2021. Seventy-four patients undergoing general anaesthesia for elective surgery requiring the administration of rocuronium and subject to continuous EMG neuromuscular monitoring were included. PK/PD-simulated TOF ratios were plotted and synchronised with their measured electromyographic counterparts and their differences analysed by means of Predictive Error derivatives (Varvel criteria). Published rocuronium PK/PD models overestimated clinically registered TOF ratios. The models of Wierda, Szenohradszky, Cooper, Alvarez-Gomez and McCoy showed significant predictive consistency between themselves, displaying Median Absolute Performance Errors between 38% and 41%, and intra-individual differences (Wobble) between 14 and 15%. The Kleijn model outperformed the former with a lower Median Absolute Performance Error (16%, 95%CI [0.01; 57]) and Wobble (11%, 95%CI [0.01; 34]). All models displayed considerably wide 95% confidence intervals for all performance metrics, suggesting a significantly variable performance. Simulated TOF ratios based on published PK/PD models do not accurately predict real intraoperative TOF ratio dynamics. NCT04518761 (clinicaltrials.gov), registered on 19 August 2020. • Existing rocuronium PK/PD models innaccurately predict intraoperative TOF ratios. • These findings challenge the common rationale that "time after dose" is safe to exclude residual paralysis. • Quantitative neuromuscular monitoring is essential to assure an adequate recovery. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
7. Prospective clinical validation of the Eleveld propofol pharmacokinetic-pharmacodynamic model in general anaesthesia.
- Author
-
Vellinga, Remco, Hannivoort, Laura N., Introna, Michele, Touw, Daan J., Absalom, Anthony R., Eleveld, Douglas J., and Struys, Michel M.R. F.
- Subjects
- *
PROPOFOL , *ANESTHESIA , *DRUG administration , *BLOOD sampling , *PHARMACOKINETICS , *BIOLOGICAL models , *OBESITY , *RESEARCH , *GENERAL anesthesia , *INTRAVENOUS therapy , *BODY weight , *AGE distribution , *RESEARCH methodology , *EVALUATION research , *MEDICAL cooperation , *INTRAVENOUS anesthetics , *COMPARATIVE studies , *LONGITUDINAL method ,RESEARCH evaluation - Abstract
Background: Target-controlled infusion (TCI) systems incorporating pharmacokinetic (PK) or PK-pharmacodynamic (PK-PD) models can be used to facilitate drug administration. Existing models were developed using data from select populations, the use of which is, strictly speaking, limited to these populations. Recently a propofol PK-PD model was developed for a broad population range. The aim of the study was to prospectively validate this model in children, adults, older subjects, and obese adults undergoing general anaesthesia.Methods: The 25 subjects included in each of four groups were stratified by age and weight. Subjects received propofol through TCI with the Eleveld model, titrated to a bispectral index (BIS) of 40-60. Arterial blood samples were collected at 5, 10, 20, 30, 40, and 60 min after the start of propofol infusion, and every 30 min thereafter, to a maximum of 10 samples. BIS was recorded continuously. Predictive performance was assessed using the Varvel criteria.Results: For PK, the Eleveld model showed a bias < ±20% in children, adults, and obese adults, but a greater bias (-27%) in older subjects. Precision was <30% in all groups. For PD, the bias and wobble were <5 BIS units and the precision was close to 10 BIS units in all groups. Anaesthetists were able to achieve intraoperative BIS values of 40-60 using effect-site target concentrations about 85-140% of the age-adjusted Ce50.Conclusions: The Eleveld propofol PK-PD model showed predictive precision <30% for arterial plasma concentrations and BIS predictions with a low (population) bias when used in TCI in clinical anaesthesia practice. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
8. Clinical validation of pharmacokinetic/pharmacodynamic models for propofol infusion. Response to Br J Anaesth 2021: 126: e172-4.
- Author
-
Vellinga, Remco, Hannivoort, Laura N., Koomen, Jeroen V., Colin, Pieter, Absalom, Anthony R., Struys, Michel M.R.F., and Eleveld, Douglas J.
- Subjects
- *
PROPOFOL , *PHARMACOKINETICS , *PHARMACODYNAMICS - Published
- 2021
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.